Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.8852W HIGH $16.68
Volume
135.49 K
Value Traded
1.22 M
Short % Float
5.86%
Days to Cover
10.1
+1.75%Week
-8.77%1 Month
-28.07%3 Month
-28.24%6 Month
-84.99%5 Year
-99.53%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
304.88 M
EPS (TTM)
-1.31
P/E Ratio
-
Ent. Value
124.90 M
Total Shares
34.88 M
Float Shares
34.01 M
Insiders
2.51%
Institutions
99.24%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BNTC Catalyst Timeline
Dated clinical, regulatory and corporate events for Benitec Biopharma Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Benitec Biopharma Inc.
171Total events
6Upcoming
30Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Interim Efficacy DataBB-301Clinical Data
Positive interim Phase 1b/2a results for high dose BB-301 and durable improvements for low dose BB-301
Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagiasource ↗
▲Safety Data UpdateBB-301Clinical Data
No Serious Adverse Events in any patient treated with BB-301 to date
Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagiasource ↗
●FDA Feedback ReceivedBB-301FDA Meeting
FDA feedback received following Type C meeting; additional data requested
Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagiasource ↗
◆Topline ReadoutBB-301Clinical Data
Updated interim clinical study results for Cohort 1 and Cohort 2 expected in 2H-2026
Oculopharyngeal Muscular Dystrophy (OPMD)source ↗
●Type C MeetingBB-301FDA Meeting
Type C meeting with FDA held for BB-301 pivotal study
Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagiasource ↗
●Quarterly UpdateCorporate
Benitec reported full year 2026 financial results for fiscal year ended June 30, 2026
◆Oral PresentationBB-301Presentation
Oral presentation of interim Phase 1b/2a results for BB-301 at ASGCT 2026
Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagiasource ↗
◆Topline ReadoutBB-301Clinical Data
Interim clinical results for Cohort 1 and Cohort 2 presented at ASGCT
Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagiasource ↗
▲Enrollment UpdateBB-301Trial
Cohort 2 enrollment continues; Patient 1 and Patient 2 safely treated with high dose BB-301
Oculopharyngeal Muscular Dystrophy (OPMD)source ↗
◆FDA Feedback ReceivedBB-301FDA Meeting
FDA engagement planned in mid-2026 to confirm pivotal study design
oculopharyngeal muscular dystrophy (OPMD)source ↗
◆Interim AnalysisBB-301Trial
Interim clinical results update for Cohort 2 planned for mid-2026
Oculopharyngeal Muscular Dystrophy-related Dysphagiasource ↗
◆Type B MeetingBB-301FDA Meeting
FDA meeting to formalize pivotal BB-301 study design expected mid-year
Oculopharyngeal Muscular Dystrophy-related Dysphagiasource ↗
◆Oral PresentationBB-301Presentation
Industry Forum Breakfast presentation highlighting key clinical results for BB-301 at 2026 MDA Clinical and Scientific Conference
Oculopharyngeal Muscular Dystrophy (OPMD)source ↗
◆Poster PresentationBB-301Presentation
Late-breaking poster presentation of interim clinical study results at MDA Conference
Oculopharyngeal Muscular Dystrophysource ↗
▲Topline ReadoutBB-301Clinical Data
Interim clinical results for high dose BB-301 (Cohort 2) and low dose BB-301 (Cohort 1) announced
Oculopharyngeal Muscular Dystrophysource ↗
▲Full ResultsBB-301Clinical Data
Long-term efficacy trends for low dose BB-301 at 24-months post treatment
Oculopharyngeal Muscular Dystrophysource ↗
▲Poster PresentationBB-301Presentation
Late-breaking abstract for BB-301 presented at MDA Clinical and Scientific Conference in March 2026
Oculopharyngeal Muscular Dystrophy (OPMD)source ↗
▲AbstractBB-301Presentation
Late-breaking abstract accepted for BB-301 Phase 1b/2a study at MDA Conference
Oculopharyngeal Muscular Dystrophysource ↗
▲Primary Endpoint MetBB-301Clinical Data
All 4 Cohort 1 completers were formal responders at 12-month follow-up
Oculopharyngeal Muscular Dystrophy-related Dysphagiasource ↗
▲Long Term DataBB-301Clinical Data
Patient 1 of Cohort 1 completed 24-month follow-up with deepening improvements
Oculopharyngeal Muscular Dystrophy-related Dysphagiasource ↗
▲Full ResultsBB-301Clinical Data
Patient 1 completed 24-month follow-up with deepening improvements
oculopharyngeal muscular dystrophy (OPMD)source ↗
▲Fast Track DesignationBB-301Designation
Fast Track Designation granted for BB-301
Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagiasource ↗
▲Topline ReadoutBB-301Clinical Data
Positive interim clinical study results from Phase 1b/2a trial of BB-301: 100% responder rate in Cohort 1
Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagiasource ↗
▼Equity OfferingCorporate
Proposed underwritten public offering of common stock and concurrent registered direct offering
▲Topline ReadoutBB-301Clinical Data
Positive interim clinical results for BB-301 Phase 1b/2a trial: 100% response rate in Cohort 1
OPMD with dysphagiasource ↗
▲Fast Track DesignationBB-301Designation
FDA grants Fast Track designation for BB-301
OPMD with dysphagiasource ↗
●Oral PresentationBB-301Presentation
Webcast presentation of interim BB-301 Phase 1b/2a clinical study update
OPMD with dysphagiasource ↗
▲Fast Track DesignationBB-301Designation
Fast Track Designation granted for BB-301 in November 2025
Oculopharyngeal Muscular Dystrophy-related Dysphagiasource ↗
▲First Patient DosedBB-301Trial
First patient of Cohort 2 successfully treated with BB-301
Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagiasource ↗
◆Enrollment UpdateBB-301Trial
Enrollment of Cohort 2 expected to begin in Q4 2025
Oculopharyngeal Muscular Dystrophy (OPMD)source ↗
◆Timing GuidanceBB-301Presentation
Additional clinical study updates for Cohort 1 planned for Q4 2025
Oculopharyngeal Muscular Dystrophy (OPMD)source ↗
◆Additional DataBB-301Clinical Data
Additional clinical updates for Subjects enrolled in BB-301 Phase 1b/2a study
Oculopharyngeal Muscular Dystrophy (OPMD)source ↗
▲DSMB ReviewBB-301Trial
DSMB review completed for all six subjects in Cohort 1, recommended continuation
Oculopharyngeal Muscular Dystrophy (OPMD)source ↗
▲First Patient DosedBB-301Trial
Sixth and final subject of Cohort 1 treated with low dose of BB-301
Oculopharyngeal Muscular Dystrophy (OPMD)source ↗
▲Enrollment CompleteBB-301Trial
Sixth and final subject of Cohort 1 treated with low dose BB-301
OPMDsource ↗
◆Enrollment MilestoneBB-301Trial
Sixth and final subject of Cohort 1 anticipated to receive low-dose BB-301 in Q2 2025
Oculopharyngeal Muscular Dystrophy (OPMD)source ↗
Past FDA Catalysts and PDUFA Decisions
How BNTC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-27 | BB-301 | Phase 1b/2a interim results | Phase 1b/2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 77%
Micro Cap(rank 506 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BB-301 Gene therapyNCT06185673 | Oculopharyngeal Muscular Dystrophy | Phase 1 | RECRUITING | 30 | Nov 1, 2040 |
Clinical Trial Results
Readouts, endpoints and source filings for every BNTC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BB-301 Fast TrackOrphan | Oculopharyngeal Muscular Dystrophy (OPMD) | Phase 1b/2a | 2026-10-28 | response rate: 100%; cohort 1 response rate: 100%; cohort 2 response rate: 100%; cohort 1 throat emptying improvement: 67%; cohort 2 throat emptying improvement: 100%Read More | Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BUCHI J KEVINDirector | Disposition | -51,813 52,097 held | $0.00 | 06/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BNTC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.2 % | 24.75 M | 1.85 M |
BNTC Institutional Ownership Trends
BNTC Short Interest
Shares sold short, counted twice a month.
5.86%
Short % of Float
of tradable shares sold short
2.0M
Shares Sold Short
-2.3% vs prior count
10.1 Very high
Days to Cover
trading days of normal volume to buy every short share back
197.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BNTC ranks across every disease it competes in
Competitive Position is a premium feature
See how BNTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBNTC News
BNTC▼ -1%today
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301
Benitec Biopharma announced positive interim results from its Phase 1b/2a study of BB-301 for OPMD. All patients treated with BB-301 showed robust improvements in swallowing function, with 100% response rate. High dose patients demonstrated greater improvements in throat emptying and swallowing capacity at the three-month follow-up. The company plans to advance to a pivotal study in mid-2027.
Read more →BNTCBenitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
Benitec Biopharma announced a regulatory update following a Type C meeting with the FDA regarding its BB-301 pivotal study. The trial is set to begin in mid-2027, with the FDA requesting additional data from the OPMD Natural History Study. Interim results from the ongoing Phase 1b/2a study will be presented at the ESGCT Annual Congress in October 2026.
Read more →BNTC▼ -8.5%on this news
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Benitec Biopharma reported its financial results for the fiscal year 2026, highlighting significant progress in its BB-301 clinical trial for OPMD-related dysphagia. All patients in Cohort 1 have completed follow-up, and Cohort 2 is fully enrolled. The company held a Type C meeting with the FDA to discuss pivotal study design, with interim results to be presented at an upcoming congress. Despite a net loss increase, Benitec remains financially robust with $180 million in cash.
Read more →BNTCBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma reported its third-quarter 2026 financial results alongside key updates on its BB-301 clinical program for Oculopharyngeal Muscular Dystrophy. The results showcased promising clinical data, demonstrating durable responses in patients treated with BB-301. The Company announced plans to engage the FDA on the pivotal study design mid-year and has successfully treated patients in ongoing clinical trials. With a robust cash position, Benitec is well-prepared to advance BB-301, positioning itself closer to potential approval.
Read more →BNTCBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Benitec Biopharma announced the acceptance of interim results from its BB-301 Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD). The results, which show durable improvements in patients, will be presented at the 2026 ASGCT Annual Meeting. BB-301 is a unique gene therapy targeting dysphagia in OPMD patients, with no approved therapies currently available.
Read more →BNTCBenitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
Benitec Biopharma Inc. is set to host an Industry Forum Breakfast at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026. The event will showcase the clinical results of BB-301, a treatment in development for Oculopharyngeal Muscular Dystrophy (OPMD), which currently has no approved therapies. CEO Jerel A. Banks will present findings showing substantial improvements in dysphagic symptoms for patients treated with BB-301, emphasizing its potential to transform OPMD treatment. The conference is aimed at industry stakeholders and will also be accessible via live stream.
Read more →BNTC▲ +10.7%on this newsshared move
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma announced positive interim results from its Phase 1b/2a study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). Patients receiving both low and high doses of BB-301 showed significant improvements in swallowing function, with durable effects lasting up to two years. The high dose demonstrated a robust response, indicating potential for disease-modifying outcomes.
Read more →BNTCBenitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma has announced the acceptance of a late-breaking abstract for its BB-301 Phase 1b/2a clinical study at the Muscular Dystrophy Association Clinical & Scientific Conference. The study focuses on treating Oculopharyngeal Muscular Dystrophy (OPMD) patients with moderate dysphagia. Interim results for both Cohort 1 and Cohort 2 will be presented, highlighting the potential of BB-301 as a treatment option.
Read more →BNTCBenitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma reported positive results from its BB-301 Phase 1b/2a study, with all four patients in Cohort 1 showing durable responses after 12 months. Patient 1 continued to experience significant improvements at the 24-month follow-up. The company plans to engage with the FDA regarding the pivotal study design in mid-2026 and has received Fast Track Designation for BB-301.
Read more →BNTCBenitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
Benitec Biopharma has announced promising long-term results from its BB-301 Phase 1b/2a clinical trial for treating dysphagia associated with oculopharyngeal muscular dystrophy. Notably, Patient 1 showed marked disease-modifying improvements over a 24-month follow-up period, reporting significant reductions in post-swallow residue and symptom burden. All four patients in the initial cohort completed the 12-month follow-up and showed durable responses to the treatment, with further evaluations expected moving forward. The company plans to engage with the FDA regarding the next steps in development.
Read more →BNTCBenitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
Benitec Biopharma announced its first quarter 2026 financial results, highlighting significant achievements including the FDA granting Fast Track Designation to its lead product BB-301. The interim results from the Phase 1b/2a trial indicated a 100% responder rate among patients in Cohort 1. Additionally, the company raised $100 million in a public offering to support further development of its Oculopharyngeal Muscular Dystrophy program. However, the financial report showed an increased comprehensive loss and net loss for the period compared to the previous year.
Read more →BNTC▼ -24%on this news
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
Benitec Biopharma Inc. has announced the pricing of a $100 million common stock offering, which includes an underwritten public offering of 5,930,000 shares and a direct offering of 1,481,481 shares. The proceeds will be used to support product candidate programs and general corporate purposes. The offerings are set to close on November 7, 2025.
Read more →BNTC▼ -24%on this newsshared move
Benitec Biopharma Inc. Announces Proposed Public Offering
Benitec Biopharma Inc. has announced a proposed public offering of its common stock, alongside a registered direct offering with Suvretta Capital. The offerings are set to close on November 7, 2025, pending customary conditions. The company aims to raise funds to support its gene therapy initiatives, although market conditions may affect the final terms.
Read more →BNTCBenitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Benitec Biopharma received FDA Fast Track designation for BB-301 after interim results showed a 100% response rate in its Phase 1b/2a trial. All six patients in Cohort 1 met statistical criteria for response to the gene therapy. The treatment led to sustained improvements in swallowing function and reduced symptom burden for patients with OPMD. The company plans to meet with regulators in 2026 to confirm the pivotal study design.
Read more →BNTCBenitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Benitec Biopharma has appointed Dr. Sharon Mates to its Board of Directors, effective November 2, 2025. Dr. Mates, who has a strong background in biotechnology, is expected to contribute significantly to the company's BB-301 program aimed at treating Oculopharyngeal Muscular Dystrophy (OPMD). Her experience in advancing therapies from discovery to commercialization will be valuable as Benitec seeks regulatory approval for its innovative treatments.
Read more →BNTCBenitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Benitec Biopharma announced an upcoming update on its Phase 1b/2a clinical study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). The update will cover six patients from the initial cohort. The webcast is scheduled for November 3, 2025, at 8:00 am EST, reflecting the company's commitment to transparency in its clinical trials.
Read more →BNTCBenitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
Benitec Biopharma reported its financial results for the year ending June 30, 2025, highlighting an increase in operational losses and expenses. The company anticipates interim results for Cohort 1 of its BB-301 Phase 1b/2a study in Q4 2025 and has received approval to begin enrollment for Cohort 2. The financial report indicates a substantial cash reserve of $97.7 million.
Read more →BNTC▲ +9.7%on this news
Benitec Biopharma Provides Operational Updates
Benitec Biopharma announced that the independent Data Safety Monitoring Board has recommended the continuation of subject enrollment for its Phase 1b/2a clinical study of BB-301. The sixth and final subject of Cohort 1 was treated safely, and enrollment for Cohort 2 is expected to begin in Q4 2025. The company is optimistic about the safety profile of BB-301, which utilizes a local delivery method.
Read more →BNTCBenitec Biopharma Releases Third Quarter 2025 Financial Results
Benitec Biopharma Inc. announced its financial results for the third fiscal quarter of 2025, which ended on March 31, 2025. The company reported a significant increase in expenses, totaling $10.2 million, and a net loss of $9.4 million, up from $4.3 million in the same period the previous year. Despite these financial challenges, Benitec is focused on the clinical development of BB-301 for treating dysphagia in OPMD patients and has successfully treated all subjects in the first cohort. The company plans to enroll more subjects at a higher dose later this year and anticipates further clinical updates in the fourth quarter.
Read more →BNTCBenitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
Benitec Biopharma Inc. announced a $30 million common stock offering, consisting of both an underwritten and a registered direct offering. The company plans to use the net proceeds to support its developmental programs, working capital, and general corporate purposes. The offerings are expected to close on March 26, 2025, with Suvretta Capital participating as a long-term investor. The SEC has approved a registration statement for these securities, following which a prospectus supplement will be filed.
Read more →About Benitec Biopharma Inc.
Headquarters3940 TRUST WAY, HAYWARD, CA, 94545
BIOPHARMAWATCH ELITE PLUS
Trade the next BNTC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime